JPMorgan Chase & Co. Has $123,000 Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC)

JPMorgan Chase & Co. lifted its position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) by 257.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 71,721 shares of the company’s stock after purchasing an additional 51,664 shares during the period. JPMorgan Chase & Co. owned 0.08% of Century Therapeutics worth $123,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Century Therapeutics by 3.5% during the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after purchasing an additional 32,614 shares during the period. State Street Corp grew its holdings in shares of Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after purchasing an additional 57,323 shares in the last quarter. Wellington Management Group LLP bought a new stake in Century Therapeutics during the third quarter worth about $284,000. Renaissance Technologies LLC lifted its holdings in shares of Century Therapeutics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after acquiring an additional 9,500 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Century Therapeutics by 141.7% during the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after purchasing an additional 44,155 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Price Performance

IPSC stock opened at $0.82 on Monday. The company’s 50-day moving average is $1.13 and its 200-day moving average is $1.46. The stock has a market capitalization of $69.78 million, a PE ratio of -0.44 and a beta of 1.76. Century Therapeutics, Inc. has a 1 year low of $0.78 and a 1 year high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.08. The business had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. During the same quarter in the prior year, the company earned ($0.55) earnings per share. On average, analysts anticipate that Century Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on IPSC shares. Chardan Capital lowered their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Finally, Piper Sandler decreased their target price on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics has an average rating of “Buy” and an average target price of $10.00.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.